Jyong Biotech Ltd. (NASDAQ:MENS) Sees Significant Decrease in Short Interest

Jyong Biotech Ltd. (NASDAQ:MENS) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totaling 234,254 shares, a decline of 18.9% from the March 15th total of 288,865 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average trading volume of 201,892 shares, the short-interest ratio is presently 1.2 days.

Jyong Biotech Trading Down 1.5%

Shares of Jyong Biotech stock traded down $0.04 on Thursday, reaching $2.59. 100,408 shares of the company were exchanged, compared to its average volume of 139,842. Jyong Biotech has a one year low of $1.43 and a one year high of $67.00. The company has a 50-day moving average of $2.15 and a 200 day moving average of $17.86.

Jyong Biotech (NASDAQ:MENS) last announced its quarterly earnings data on Friday, January 9th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Jyong Biotech presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MENS. BNP Paribas Financial Markets acquired a new stake in shares of Jyong Biotech during the 3rd quarter worth $67,000. Geode Capital Management LLC lifted its position in shares of Jyong Biotech by 19.6% during the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after buying an additional 10,538 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Jyong Biotech during the 4th quarter worth $49,000. Millennium Management LLC bought a new stake in shares of Jyong Biotech during the 3rd quarter worth $512,000. Finally, Man Group plc bought a new stake in shares of Jyong Biotech during the 4th quarter worth $56,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.